Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NCT02785562 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

OTHER: Assessment of PDL1 expression

Sponsor

Groupe Francais De Pneumo-Cancerologie